Cargando…

SARS‐CoV‐2 infection in hematological patients during allogenic stem cell transplantation: A double case report

Despite severe immunosuppression due to conditioning chemotherapy for acute myeloid leukemia, COVID‐19 did not lead to clinical deterioration or death, thus raising the question of the impact of immunosuppressive treatment on clinical course evolution.

Detalles Bibliográficos
Autores principales:	Alexandra, Van Uytvanck, Sebastian, Wittnebel, Nathalie, Meuleman, Angela, Loizidou, Jean‐Corentin, Salengros, Chloé, Spilleboudt
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8287311/ https://www.ncbi.nlm.nih.gov/pubmed/34295477 http://dx.doi.org/10.1002/ccr3.4439

Ejemplares similares

Factors associated with SARS-CoV-2 infection and outcome in patients with solid tumors or hematological malignancies: a single-center study
por: Goudsmit, Anouk, et al.
Publicado: (2021)

ABCL-013: Factors Associated with SARS-CoV-2 Infection and Outcome in Patients with Solid Tumors or Hematological Malignancies: A Single-Center Study
por: Goudsmit, Anouk, et al.
Publicado: (2021)

Poster: ABCL-013: Factors Associated with SARS-CoV-2 Infection and Outcome in Patients with Solid Tumors or Hematological Malignancies: A Single-Center Study
por: Goudsmit, Anouk, et al.
Publicado: (2021)

New Perspectives in Treating Acute Myeloid Leukemia: Driving towards a Patient-Tailored Strategy
por: Andreozzi, Fabio, et al.
Publicado: (2022)

Immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer: a systematic review and meta-analysis
por: Martins-Branco, Diogo, et al.
Publicado: (2022)

Allogeneic hematopoietic stem cell transplantation for non-malignant hematological disorders
por: Mahmoud, Hossam K., et al.
Publicado: (2015)

Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Hematological Malignancies
por: Zahid, Mohammad Faizan, et al.
Publicado: (2014)

Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies
por: Pavletic, ZS, et al.
Publicado: (1998)

Antibody Response to Sars-Cov-2 Vaccination in Patients Following Allogeneic Hematopoietic Cell Transplantation
por: Cicin-Sain, Caroline, et al.
Publicado: (2021)

PB2427: THE RISK FACTORS ON THE SEVERITY OF SARS-COV2 OMICRON VARIANT INFECTION IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES AFTER ALLOGENEIC HEMATOPOIEITC STEM CELL TRANSPLANTATION
por: LI, Zhihui, et al.
Publicado: (2023)

Outcomes of allogeneic stem cell transplantation for patients with hematologic diseases ≥60 years old
por: Shima, Takahiro, et al.
Publicado: (2023)

Serologic Responses following a Single Dose of SARS-Cov-2 Vaccination in Allogeneic Stem Cell Transplantation Recipients
por: Easdale, Sandra, et al.
Publicado: (2021)

Antibody Response to SARS-CoV-2 Vaccination in Patients following Allogeneic Hematopoietic Cell Transplantation
por: Huang, Alice, et al.
Publicado: (2022)

2696. Breakthrough Toxoplasmosis While on Atovaquone Prophylaxis Following Allogeneic Hematologic Stem Cell Transplantation
por: Chueng, Teresa A, et al.
Publicado: (2019)

Outcomes of two-step haploidentical allogeneic stem cell transplantation in elderly patients with hematologic malignancies
por: Bi, Xia, et al.
Publicado: (2022)

Allogeneic haematopoietic stem cell transplantation from SARS-CoV-2 positive donors
por: Leclerc, Mathieu, et al.
Publicado: (2021)

Pediatric allogeneic stem cell transplantation from adult SARS-COV-2 positive donor
por: Memon, Shahbaz, et al.
Publicado: (2023)

Rapid cardiovascular aging following allogeneic hematopoietic cell transplantation for hematological malignancy
por: Dillon, Hayley T., et al.
Publicado: (2022)

Association between Prior Cytotoxic Therapy, Antecedent Hematologic Disorder, and Outcome after Allogeneic Hematopoietic Cell Transplantation in Adult Acute Myeloid Leukemia
por: Orvain, Corentin, et al.
Publicado: (2023)

Antibody responses to SARS-CoV2 vaccination in allogeneic hematopoietic stem cell transplant recipients
por: Mamez, Anne-Claire, et al.
Publicado: (2021)

Determinants of SARS-CoV-2 waning immunity in allogeneic hematopoietic stem cell transplant recipients
por: Leclerc, Mathieu, et al.
Publicado: (2022)

Complete hematologic response after belinostat treatment and allogeneic stem cell transplantation for multiple relapsed/refractory angioimmunoblastic T‐cell lymphoma: A case report
por: Camus, Vincent, et al.
Publicado: (2023)

Primary Graft Failure after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies
por: Olsson, Richard F., et al.
Publicado: (2015)

P1351: CHARACTERIZING ALLOGENEIC STEM CELL TRANSPLANTATION SAFETY IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES AFTER PEMBROLIZUMAB THERAPY
por: Kuruvilla, J., et al.
Publicado: (2022)

Aseptic Meningitis after Recovery from SARS-CoV-2 in an Allogeneic Stem Cell Transplant Recipient
por: Basher, Fahmin, et al.
Publicado: (2021)

Anti-SARS-CoV-2 Immune Responses in Patients Receiving an Allogeneic Stem Cell or Organ Transplant
por: Atanackovic, Djordje, et al.
Publicado: (2021)

Infectious complications after second allogeneic hematopoietic cell transplant in adult patients with hematological malignancies
por: Maurer, Stephen M., et al.
Publicado: (2022)

Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies
por: Xuan, Li, et al.
Publicado: (2012)

Very Long Term Stability of Mixed Chimerism after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Hematologic Malignancies
por: Levrat, Emmanuel, et al.
Publicado: (2015)

Changes in serum uric acid levels after allogeneic hematologic stem cell transplantation: A retrospective cohort study
por: Joo, Sang Hyun, et al.
Publicado: (2016)

Exercise before, during, and after Hospitalization for Allogeneic Hematological Stem Cell Transplant: A Feasibility Randomized Controlled Trial
por: Santa Mina, Daniel, et al.
Publicado: (2020)

Response to BNT162b2 Sars-Cov-2 Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant
por: Saraceni, Francesco, et al.
Publicado: (2021)

Common seasonal respiratory virus infections in allogeneic stem cell transplant recipients during the SARS-COV-2 pandemic
por: De la Puerta, Rosalía, et al.
Publicado: (2021)

Fecal microbiota transplantation before or after allogeneic hematopoietic transplantation in patients with hematologic malignancies carrying multidrug-resistance bacteria
por: Battipaglia, Giorgia, et al.
Publicado: (2019)

The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China—recommendations from the Chinese Society of Hematology
por: Xu, Lanping, et al.
Publicado: (2018)

Clinicopathologic characteristics of secondary squamous cell carcinoma of head and neck in survivors of allogeneic hematopoietic stem cell transplantation for hematologic malignancies
por: Chaulagain, Chakra P., et al.
Publicado: (2018)

Treosulfan–fludarabine–thiotepa-based conditioning treatment before allogeneic hematopoietic stem cell transplantation for pediatric patients with hematological malignancies
por: Kalwak, Krzysztof, et al.
Publicado: (2020)

Anti-Thymocyte Globulin Prophylaxis in Patients With Hematological Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: An Updated Meta-Analysis
por: Yang, Xue, et al.
Publicado: (2021)

The Burden of Survivorship on Hematological Patients—Long-Term Analysis of Toxicities after Total Body Irradiation and Allogeneic Stem Cell Transplantation
por: Oertel, Michael, et al.
Publicado: (2021)

Interleukin-10-592 polymorphism: impact on relapse and survival after allogeneic hematopoietic stem cell transplantation in children with hematological malignancies
por: Schwenk, Laura, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_v5l7ts0j7pl1630efaa0iltvh3